Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by Icahn School of Medicine at Mount Sinai
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Roche Pharma AG
QIAGEN Marseille
Information provided by (Responsible Party):
Ronald Hoffman, Mount Sinai School of Medicine Identifier:
First received: December 6, 2010
Last updated: June 4, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)